Summary. Introduction: The Khorana score is a validated risk assessment score for estimating the risk of symptomatic venous thromboembolism (VTE) in outpatients with cancer. The objective of this study was to assess the Khorana score for predicting the development of VTE in cancer patients during hospital admission. Methods: We conducted an analysis of consecutive, adult cancer patients hospitalized for medical reasons between January and June 2010 in three academic medical centers. Information on objectively diagnosed, symptomatic VTE during hospitalization, use of anticoagulant thromboprophylaxis (TP) and Khorana score variables at the time of admission was collected. Results: A total of 1398 patients were included. Mean age was 62 years, 51.2% were male, and mean BMI was 25.9 kg m À2 . The most frequent reasons for hospitalization were chemotherapy administration (22.3%), followed by pain control and palliation (21.4%). The overall incidence of VTE was 2.9% (95% CI, 2.0-3.8%), occurring in 5.4% (95% CI,
Introduction
Venous thromboembolism (VTE) occurs commonly in patients with cancer, leading to increased morbidity and mortality [1] . Compared to patients without cancer, those with cancer have a higher risk of VTE with an associated higher mortality [2, 3] . Hospitalization increases the risk of VTE [4] and thromboprophylaxis has been shown to mitigate this in studies including largely non-cancer patients [5] [6] [7] . As cancer-specific anticoagulant thromboprophylaxis (TP) trials have not been conducted, current clinical practice guideline recommendations for TP in hospitalized patients may not be applicable in those with cancer [8] [9] [10] [11] . The thrombotic risk is heightened in cancer patients because of multiple factors, including cancer type, stage, anatomic location, antineoplastic therapy and invasive procedures [12] . Both cancerand patient-specific factors commonly found in patients with cancer (such as thrombocytopenia) also increase the risk of bleeding in acutely ill hospitalized medical patients [13] . Given that cancer patients frequently need inpatient care for issues ranging from diagnosis to management of cancer-and therapyrelated complications, there is an unmet clinical need for a VTE risk assessment tool for hospitalized patients with cancer.
Multiple risk assessment models have been developed to aid in determining the risk of VTE in cancer patients [14] [15] [16] [17] [18] [19] but none have been developed for the inpatient population. The Khorana score was developed and validated in a large cohort of outpatients and has been shown to predict VTE risk in other settings [16, [20] [21] [22] . The Khorana score separates patients into low (score = 0), intermediate (score = 1-2) or high (score ≥ 3) risk categories for developing VTE based on tumor type, complete blood count and body mass index (BMI) [16] .
The aim of this study is to evaluate the Khorana score as a risk stratification method for predicting development of VTE in hospitalized patients with cancer. Secondary aims are to determine the use of anticoagulant TP and the risk of bleeding among patients in different Khorana risk groups, and the effect of anticoagulant TP on the incidence of VTE and bleeding.
Methods

Study design, setting and patient selection
This was a retrospective cohort study conducted in three academic medical centers in Canada. Each institution's ethics review board approved the study prior to data collection. All consecutive adult patients with active cancer admitted to hospital for longer than 24 h between January and June 2010 were eligible for inclusion. If a patient was admitted multiple times during the study period, only the first admission was included. Patients who required therapeutic anticoagulation during admission for a known or pre-existing thrombotic condition (e.g. atrial fibrillation) or with incomplete data were excluded from analysis.
Data collection
Data were collected on standardized case report forms in consecutive patients meeting eligibility criteria. Collected data included patient demographics (age and sex), TP (defined as prophylactic doses of low-molecularweight heparin [LMWH] (1 point) and BMI ≥ 35 kg m À2 (1 point). Patients for whom the above data were unavailable were excluded from analysis. The original Khorana score assigned 1 point for hemoglobin < 100 g L À1 or use of erythropoiesis-stimulating agents (ESAs), but data on ESA use were not recorded in this cohort because ESAs were not routinely used in any of the study's medical centers. A Khorana score was calculated for each patient based on these parameters at the time of hospital admission.
Outcomes
The primary outcome measure was objectively documented symptomatic VTE during hospitalization. Secondary outcome measures include the use of TP in patients, major bleeding and death. VTE and major bleeding were classified according to the definitions specified by the International Society on Thrombosis and Haemostasis [23] .
Statistical analysis
Descriptive statistics were used to summarize patient characteristics. The proportions of patients in each Khorana risk category with symptomatic VTE, major bleeding and death in hospital were reported with 95% confidence intervals (CIs). The cohort was divided into two groups based on occurrence of VTE. Patients who developed VTE were compared to those who did not develop VTE with respect to individual Khorana scores as well as baseline characteristics. These analyses were repeated based on use of anticoagulant TP. Categorical data were compared using the Pearson chi-squared test and were expressed as percentages. The Fisher's exact test was used in place of the Pearson chi-squared test when 20% or more expected cell counts were ≤ 5. Continuous data were compared using a Student's t-test and expressed using the means and standard deviations. Odds ratios (ORs) with 95% confidence intervals were reported to determine the association between Khorana score category and VTE as well as anticoagulant TP. Statistical significance was defined as alpha less than 0.05. All statistical analyses were performed using IBM SPSS Statistics 24 (New York, NY, USA).
Results
A total of 2295 patients were reviewed and 1398 patients were eligible for inclusion (Fig. 1 Fig. 3 ).
Discussion
This retrospective cohort study demonstrated that among cancer patients who are hospitalized for medical reasons, the Khorana score is predictive for development of symptomatic VTE during hospitalization. These findings suggest that the Khorana score may be a useful tool for tailoring inpatient anticoagulant thromboprophylaxis. In particular, our results suggest that TP can be avoided in those with a low Khorana score as the incidence of VTE was only 1.4%. This is clinically impactful as the low-risk group represented about 30% of the cohort. Analysis of patients admitted for chemotherapy vs. those admitted for other medical reasons provided results consistent with the overall findings. The Khorana score is a VTE risk model derived from a prospective observational study of outpatients with cancer initiating chemotherapy [16] . Our multiinstitution study confirms the findings of a recent single-institution retrospective cohort study that validated the Khorana score for predicting VTE in hospitalized cancer patients [24] . This study included recursive partitioning analysis that suggested the optimal cut-point for distinguishing hospitalized patients with a higher risk of VTE is a Khorana score ≥ 2 (OR, 1.82; 95% CI, 1.23-2.69) [24] . We analyzed our data using this cut-point and found similar results, (OR, 2.3; 95% CI, 1.2-4.3). The above single-institution study included patients who were receiving therapeutic anticoagulation during hospitalization, which could lead to an underestimation of the risk of VTE during hospitalization. In contrast, our study excluded all patients who received therapeutic anticoagulation, which accounted for 12% of patients who were eligible for enrollment (Fig. 1) . The safety of administering TP in hospitalized medically ill cancer patients is unknown as the incidence of major bleeding has not been reported previously to the best of our knowledge [25] . In our study the in-hospital incidence of major bleeding was low at 1.8%, and did not differ between patients who did and did not receive TP. This low incidence is consistent with previously published rates of major bleeding at 1.2% in hospitalized, largely non-cancer acutely ill medical patients [13] .
We also examined the use of TP with respect to Khorana risk groups and VTE. Patients in the high-risk Khorana category were more likely to receive TP, suggesting that physicians may have selected patients to receive or avoid TP. This selection bias could potentially influence the observed predictive effect of the Khorana score. Our study did not demonstrate a reduction in VTE with TP. We are unable to exclude a benefit of TP given potential confounders.
Our study has limitations. Although we have a large multi-institution dataset and standardized data collection, data were collected retrospectively and a proportion of patients were excluded because of incomplete data on BMI. Data were limited to in-hospital events. Consequently, the length of stay is a potential confounder if this differed substantially between the risk groups. Thrombotic events shortly after discharge would have been missed, as it has been previously demonstrated that almost half of all hospital-associated VTEs occur after discharge [26] . This potentially underestimates the risk of VTE per risk group and might influence the impact of anticoagulant prophylaxis. Our study utilized laboratory values at admission, which is different from the original Khorana score, which used values prior to chemotherapy administration. The Khorana score itself has limitations, as it does not account for VTE risk factors such as other high-risk tumor sites (such as the CNS), prior history of VTE, thrombophilia and other biochemical parameters [27] . It is possible that the factors in the Khorana score have a different impact on VTE risk for inpatients, and prospective analysis is required to possibly yield a more appropriate prediction tool. Analysis of our data excluding patients with CNS tumors did not change our results.
Although it was reassuring to find that the total incidence of major bleeding was low and that there were no statistically significant differences in major bleeding between those who received TP and those who did not, we did not capture all factors that can predispose to bleeding and which may have influenced TP decisions.
In conclusion, we found that the Khorana score is predictive of VTE development in cancer patients admitted for medical indications. Prospective studies are needed to confirm these findings and determine if this is a useful tool for tailoring inpatient anticoagulant prophylaxis. 
